Clinical Trials Logo

Cardiovascular Disease clinical trials

View clinical trials related to Cardiovascular Disease.

Filter by:

NCT ID: NCT01065155 Completed - Diabetes Clinical Trials

Relationship of Central Blood Pressure and Pulse Wave Velocity With Target Organ Damage

LOD-DIABETES
Start date: February 2010
Phase:
Study type: Observational

Diabetic patients show an increased prevalence of non dipping arterial pressure pattern, target organ damage and elevated arterial stiffness. These alterations are associated with increased cardiovascular risk. The objectives of this study are the following: to evaluate the prognostic value of central arterial pressure and pulse wave velocity in relation to the incidence and outcome of target organ damage and the appearance of cardiovascular episodes (cardiovascular mortality, myocardial infarction, chest pain and stroke) in patients with type 2 diabetes mellitus.

NCT ID: NCT01059760 Completed - Clinical trials for Cardiovascular Disease

Expression of Longevity Genes in Response to Extended Fasting

FEELGOOD
Start date: January 2010
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate the effect of fasting on physical changes associated with cardiovascular disease.

NCT ID: NCT01054638 Completed - Clinical trials for Cardiovascular Disease

HIV Treatment and CVD Events

Start date: March 2009
Phase: N/A
Study type: Observational

Cardiovascular disease (CVD) has been associated with HIV infection. However, it is uncertain whether increased CVD rates are associated with HIV-related factors (e.g., HIV-infection or highly active antiretroviral therapy (HAART) may worsen dyslipidemia) or reflect differences in the prevalence of underlying risk factors for CVD. Furthermore, the association between initiation and duration of HAART exposure and CVD risk, including which specific drugs within the HAART classes may contribute to the increased risk, is unknown. The primary objectives of the study are therefore: 1. To estimate the absolute and relative incidence rate (IR) of CVD claims-based diagnoses among a cohort of adult patients from a large managed care population with a claims diagnosis of HIV, AIDS, or AIDS-related complex (ARC) during periods of exposure to: - Any HAART compared to no HAART exposure - HAART class [i.e., NRTIs, NNRTIs, PIs, and Other (i.e., fusion inhibitors)] compared to no HAART class exposure - Specific NRTI medications compared to no specific NRTI exposure

NCT ID: NCT01048502 Completed - Clinical trials for Cardiovascular Disease

Fenofibrate and Omega-3 Fatty Acid Modulation of Endotoxemia

FFAME
Start date: January 2010
Phase: N/A
Study type: Interventional

The purpose of this study is to better understand the anti-inflammatory benefits of two prescription medicines that are currently used to help people with cholesterol problems. Fish oil, from eating certain kinds of fish and from supplement pills, has been used to help control cholesterol and reduce inflammation (the body's response to injury or sickness). Lovaza® is the brand name for prescription strength fish oil pills. In this study, we will be looking at how Lovaza® works to help reduce inflammation in healthy volunteers. Tricor® is the brand name for prescription fenofibrate pills. Fenofibrate is a prescription medicine that many doctors give to people with high triglyceride (fat in the blood) levels. In this study, we will be looking at how Tricor® works to help reduce inflammation in healthy volunteers. Endotoxin or lipopolysaccharide (LPS) is a small part of bacteria (that is no longer living) that can cause many of the effects similar to bacterial infections in humans. However, it can be administered in very small amounts to produce a mild immune response much the same as a 'flu' like illness. Within 1 ½ -3 hours after giving LPS by vein, a response consisting of fever, chills, headache, nausea and vomiting and generalized aches and pains will occur which lasts up to 6-8 hours. In addition to the flu like symptoms, the response causes temporary changes in cholesterol, triglycerides and blood sugar. Different people respond differently to LPS. We are using LPS in this study to bring on a temporary inflammatory response in the body and to compare the responses of people who receive Lovaza® or Tricor® to the responses of people who receive a placebo (pill that does not contain medicine).

NCT ID: NCT01046435 Completed - Obesity Clinical Trials

Effects of Periodontal Therapy on Systemic Inflammation

Start date: March 2007
Phase: N/A
Study type: Interventional

The purpose of this study is to determine if treating periodontal infections (gum disease) will reduce markers of systemic inflammation in patients at risk of cardiovascular diseases.

NCT ID: NCT01043939 Completed - Clinical trials for Cardiovascular Disease

Purple Grape Juice in Improving Vascular Health in Childhood Cancer Survivors

JAVA
Start date: November 2009
Phase: Phase 1
Study type: Interventional

Rationale: Survivors of childhood cancer are at an increased risk of developing cardiovascular risk factors as well as early cardiovascular disease, likely due to the intensive therapeutic regimen used to treat their cancer. Purple grape juice (PGJ) is a rich source of flavonoids and a powerful antioxidant. Clinical studies in both diseased and healthy adults suggest that daily consumption of PGJ contributes to increased antioxidant capacity, reduced low-density lipoprotein (LDL) oxidation, and improved vasodilation. Purpose: This randomized clinical trial is evaluating whether purple grape juice can reduce oxidative stress and improve the vascular health of survivors of childhood cancer in the early stages of cardiovascular disease.

NCT ID: NCT01042977 Completed - Clinical trials for Type 2 Diabetes Mellitus

Efficacy and Safety in Patients With Type 2 Diabetes Mellitus and Cardiovascular Disease

Start date: March 2010
Phase: Phase 3
Study type: Interventional

This study is carried out to assess whether dapagliflozin improves glycemic control, decreases fasting plasma glucose levels, body weight and blood pressure when added to patient's existing medications and how it compares with their usual treatment without added dapagliflozin. Safety data will be collected and analysed to confirm that treatment with dapagliflozin is safe and well tolerated in patients who have diabetes and cardiovascular disease

NCT ID: NCT01039961 Completed - Clinical trials for Cardiovascular Disease

PK Study of IV Formulation of GW856553

Start date: February 2, 2010
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety of an IV infusion of GW856553 in healthy volunteers.

NCT ID: NCT01038518 Completed - Asthma Clinical Trials

Health2010-14: Monitoring Biomarkers of Chronic Diseases in the General Population

Health2010-4
Start date: November 2010
Phase: N/A
Study type: Observational

The overall aim of the Health2010-14 is to monitor the prevalence and trends of common chronic diseases (osteoporosis, diabetes, cardiovascular disease, asthma, allergy, and eczema) that are often un-diagnosed in the general population as well as biomarkers of micronutrient status. Specific aims include identification of novel lifestyle and genetic risk factors for the above diseases by investigating gene-lifestyle interactions.

NCT ID: NCT01038440 Completed - Clinical trials for Cardiovascular Disease

Time and Dose Evaluation of Stearidonic Acid (SDA) to Eicosapentaenoic Acid (EPA) in Red Blood Cells

NK
Start date: August 2009
Phase: N/A
Study type: Interventional

The purpose of this study is to assess the relationships between dose and time of consumption of stearidonic acid (SDA) and eicosapentaenoic acid (EPA) on EPA enrichment of red blood cell (RBC) membranes in men and women.